Patient-Derived Tumor Xenograft

Inghirami, Giorgio; Tinkey, Peggy T.; Stanchina, Elisa de; Uthamanthil, Rajesh

doi:10.1016/b978-0-12-804010-2.00027-8

Cited by 3 publications

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PDX models of colon cancer and brain tumors were successfully generated on our AF and morphologically faithfully recapitulated the original patient tumor after different generations. The PDX model preserves cell interaction and has furthered the understanding of tumor biology, tumor genetic evolution and tumor pathobiology, and shown promise for identifying new biomarkers, as well as offering a tool for developing anticancer therapies and personalized medicine for patients with cancer, and has contributed to the poor outcomes of numerous clinical trials [20,[45][46][47].…”

Section: Discussionmentioning

confidence: 99%

The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models

Teixeira

Luzzi

Martín

et al. 2022

Veterinary Sciences

View full text Add to dashboard Cite

The Barretos Cancer Hospital Animal Facility (BCHAF) is a unique facility in Brazil exclusively dedicated to working with animal models for cancer research. In this article, we briefly present our modern facility and the main experiments performed, focusing on mutant strains of mice (PTCH-knockout and ApcMin mice), xenograft models, and patient-derived xenografts (PDXs). Our results show the progress and challenges in establishing these models and the need for having an appropriate representation of our cancer population to better understand tumor biology and to identify cancer biomarkers, which could be putatively targeted, allowing for personalized therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models

Teixeira

Luzzi

Martín

et al. 2022

Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…Additionally, they are not able to support the development of all human immune cells (including monocytes, macrophages, and natural killer cells), a problem for which exogenous cytokine delivery has been explored as a potential solution. 44 In comparison to these models, genetically engineered mouse (GEM) models make it possible to model the multiple genetic alterations that often accumulate in tumors over time, in addition to the incorporation of oncogenes, the ablation of tumor suppressor genes, and the modeling of hereditary cancer through germ-line mutations. 45 example, to model pancreatic cancer, researchers developed acinar-cell-specific elastase-promoter-driven Kras G12D transgenic mice, which developed preneoplastic ductal lesions consistent with the most common oncogenic RAS mutations found in humans.…”

Section: Patient-derived Xenograft Modelsmentioning

confidence: 99%

Tissue Engineering Models for the Study of Breast Neoplastic Disease and the Tumor Microenvironment

Premaratne

Toyoda

Celie

et al. 2020

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

The development of adequate experimental models is crucial to furthering the current mechanistic understanding of the etiopathogenesis, subsequent growth, and ultimate metastasis of breast cancer, to develop targeted diagnostics and therapeutics such as the identification of new treatments for multidrug-resistant tumors and triple-negative breast cancers. The utility of new therapeutic options is limited by the platforms currently used to test their efficacy in vitro. The use of three-dimensional models, which incorporate patient-specific, primary cells, offers significant advantages over traditional two-dimensional models by providing a means of accurately recapitulating the complex tumor microenvironment. Advances in breast cancer models, in turn, stand to contribute to more efficacious breast cancer therapeutics. Herein, we review the recent advances in experimental models of breast cancer and suggest methods by which these can be used to further our understanding of said cancer.

show abstract

Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor

Wen,

Lin,

Luo

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Patients-derived xenograft (PDX) model have been widely used for tumor biological and pathological studies. However, the metabolic similarity of PDX tumor to the primary cancer (PC) is still unknown. Methods In present study, we established PDX model by engrafting primary tumor of pancreatic ductal adenocarcinoma (PDAC), and then compared the tumor metabolomics of PC, the first generation of PDX tumor (PDXG1), and the third generation of PDX tumor (PDXG3) by using 1H NMR spectroscopy. Then, we assessed the differences in response to chemotherapy between PDXG1 and PDXG3 and corresponding metabolomic differences in drug-resistant tumor tissues. To evaluate the metabolomic similarity of PDX to PC, we also compared the metabolomic difference of cell-derived xenograft (CDX) vs. PC and PDX vs. PC. Results After engraftment, PDXG1 tumor had a low level of lactate, pyruvate, citrate and multiple amino acids (AAs) compared with PC. Metabolite sets enrichment and metabolic pathway analyses implied that glycolysis metabolisms were suppressed in PDXG1 tumor, and tricarboxylic acid cycle (TCA)-associated anaplerosis pathways, such as amino acids metabolisms, were enhanced. Then, after multiple passages of PDX, the altered glycolysis and TCA-associated anaplerosis pathways were partially recovered. Although no significant difference was observed in the response of PDXG1 and PDXG3 to chemotherapy, the difference in glycolysis and amino acids metabolism between PDXG1 and PDXG3 could still be maintained. In addition, the metabolomic difference between PC and CDX models were much larger than that of PDX model and PC, indicating that PDX model still retain more metabolic characteristics of primary tumor which is more suitable for tumor-associated metabolism research. Conclusions Compared with primary tumor, PDX models have obvious difference in metabolomic level. These findings can help us design in vivo tumor metabolomics research legitimately and analyze the underlying mechanism of tumor metabolic biology thoughtfully.

show abstract

Patient-Derived Tumor Xenograft

Cited by 3 publications

References 99 publications

The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models

The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models

Tissue Engineering Models for the Study of Breast Neoplastic Disease and the Tumor Microenvironment

Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor

Contact Info

Product

Resources

About